Profound Medical Corp.
Profound Medical Corp.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||
Assets Current | ||||||||||||
Cash And Cash Equivalents At Carrying Value | 38 | 50 | 60 | 25 | 35 | 46 | 55 | |||||
Accounts And Other Receivables Net Current | 10 | 9 | 7 | 8 | 5 | 6 | 7 | |||||
Inventory Net | 10 | 9 | 8 | 8 | 8 | 7 | 6 | |||||
Assets Current | 59 | 70 | 76 | 42 | 49 | 60 | 69 | |||||
Property Plant And Equipment Net | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |||||
Finite Lived Intangible Assets Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Right Of Use Asset | 3 | 3 | 0 | 0 | 0 | 0 | 0 | |||||
Deferred Income Tax Assets Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets | 62 | 73 | 77 | 42 | 50 | 61 | 70 | |||||
Liabilities And Stockhold… | ||||||||||||
Liabilities Current | ||||||||||||
Accounts Payable Current | 1 | 2 | 2 | 1 | 1 | 1 | 1 | |||||
Accrued Liabilities And Other Liabilities | 3 | 3 | 4 | 4 | 4 | 3 | 3 | |||||
Deferred Revenue Current | 0 | 0 | 0 | 0 | 1 | 1 | 0 | |||||
Long Term Debt Current | 5 | 5 | 4 | 4 | 4 | 4 | 2 | |||||
Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Taxes Payable Current | 0 | 0 | 0 | 0 | - | - | - | |||||
Liabilities Current | 9 | 11 | 6 | 10 | 6 | 5 | 7 | |||||
Contract With Customer Liability Noncurrent | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Liability Noncurrent | 3 | 3 | - | - | 0 | 0 | 0 | |||||
Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities | 13 | 14 | 11 | 10 | 10 | 10 | 10 | |||||
Stockholders Equity | ||||||||||||
Common Stock Value | 325 | 324 | 324 | 283 | 282 | 282 | 282 | |||||
Additional Paid In Capital | 26 | 26 | 25 | 24 | 24 | 22 | 21 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 3 | 4 | 5 | 5 | 6 | 3 | 3 | |||||
Retained Earnings Accumulated Deficit | -304 | -295 | -288 | -280 | -272 | -256 | -245 | |||||
Stockholders Equity | 50 | 59 | 66 | 32 | 39 | 51 | 60 | |||||
Liabilities And Stockholders Equity | 62 | 73 | 77 | 42 | 50 | 61 | 70 | |||||
Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Issued | 37 | 36 | 36 | 30 | 30 | 30 | 30 | |||||
Shares Outstanding | 37 | 36 | 36 | 30 | 30 | 30 | 30 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.89% | -9.22% | 1.40% | - | - | - | - | - | - | - | - | - |
| 2025 | 5.82% | 20.48% | 14.06% | -25.63% | 2.44% | 9.57% | 3.94% | 20.63% | 18.11% | -17.36% | -6.68% | -8.81% |
| 2024 | - | - | - | - | - | - | - | - | - | -11.81% | -30.54% | -25.22% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Profound Medical Corp. (PROF) — SEC Financial Statements & Analysis
Profound Medical Corp. (PROF) is a surgical & medical instruments & apparatus company, incorporated in A6. Profound Medical Corp. trades on Nasdaq as: PROF. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Profound Medical Corp. reported a Gross Profit Margin of 71.79% (TTM), a Debt-to-Equity ratio of 0.25x, a Price-to-Sales (P/S) ratio of 12.67x (TTM), a Price-to-Book (P/B) ratio of 4.85x (TTM), at a market cap of $241.73M. Figures below are sourced from SEC EDGAR, as-filed.
- Gross Profit Margin TTM
- 71.79%
- Debt To Equity
- 0.25x
- P/S TTM
- 12.67x
- P/B TTM
- 4.85x
- Market Cap
- $241.73M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Profound Medical Corp. in?
Profound Medical Corp. (PROF) operates in the Surgical & Medical Instruments & Apparatus industry.
What is PROF's market cap?
Profound Medical Corp. (PROF) has a market capitalization of $241.73M as of 2026-06-30.
What is PROF's P/E ratio?
Profound Medical Corp. (PROF)'s trailing twelve month P/E ratio is 7.38x as of 2026-06-30.
What exchange does PROF trade on?
Profound Medical Corp. (PROF) trades on the Nasdaq.
Where is Profound Medical Corp. incorporated?
Profound Medical Corp. is incorporated in Ontario, Canada.